Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 550 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non Alcoholic Fatty Liver Diseases (NAFLD) Clear all
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

NCT00740610
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
GS-9450, GS-9450 Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
31
States / cities
Tucson, Arizona • Fresno, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 22, 2026, 7:18 PM EDT
Recruiting Phase 2 Interventional

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

NCT05526144
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Fibrosis
Interventions
Synthroid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Results available

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

NCT02330549
View directory record Official record
Conditions
Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Cenicriviroc 150 mg, Placebo
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Results available

Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

NCT02960204
View directory record Official record
Conditions
Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
Interventions
Emricasan, Placebo
Drug
Lead sponsor
Histogen
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
22
States / cities
Pasadena, California • Rialto, California • Palmetto Bay, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 22, 2026, 7:18 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects

NCT04481594
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
HPN-01, Placebo
Drug
Lead sponsor
Hepanova Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease

NCT04132440
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Physician
Interventions
Interview, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Not applicable Interventional

Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates

NCT00887393
View directory record Official record
Conditions
Morbid Obesity, Non-alcoholic Fatty Liver Disease
Interventions
low carbohydrate diet, low-fat diet
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 22, 2026, 7:18 PM EDT
Withdrawn No phase listed Observational

Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis

NCT05050721
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
CT imaging
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Timeline
2019 – 2021
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 1 Interventional

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

NCT06947304
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
Miricorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE

NCT04591106
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis
Interventions
Magnetic resonance imaging (MRI), Magnetic resonance elastography (MRE), Prototype MRE soft flexible passive transducer paddle
Diagnostic Test · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Week to 40 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Completed No phase listed Observational

Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference

NCT04389593
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 3 Interventional

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

NCT05935826
View directory record Official record
Conditions
Hepatic Steatosis, NAFLD, Adolescent Obesity
Interventions
Essential Amino Acid Supplement by Amino Co, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome

NCT02083367
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Results available

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

NCT03776175
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
PF-05221304 Monotherapy, PF-06865571 Monotherapy, Placebo, PF-05221304 and PF-06865571 Combination
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
29
States / cities
Bakersfield, California • Beverly Hills, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 22, 2026, 7:18 PM EDT
Terminated Not applicable Interventional Results available

Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease

NCT04576923
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis
Interventions
Velacur by Sonic Incytes
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 22, 2026, 7:18 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

NCT02913105
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis NASH
Interventions
LMB763, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Culver City, California • Cypress, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 22, 2026, 7:18 PM EDT
Terminated Phase 1 Interventional Results available

A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT06007651
View directory record Official record
Conditions
Dyslipidemias, Non-Alcoholic Fatty Liver Disease
Interventions
LY3885125, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 1 Interventional

PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

NCT05022693
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
BIO89-100
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Not applicable Interventional Results available

Obesity and Nonalcoholic Fatty Liver Disease

NCT00262964
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Niacin, fenofibrate, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT03812029
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Vonafexor, Placebo
Drug · Other
Lead sponsor
Enyo Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
North Little Rock, Arkansas • Lakewood Rch, Florida • Ocoee, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 22, 2026, 7:18 PM EDT
Completed No phase listed Observational

Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)

NCT02363309
View directory record Official record
Conditions
Fatty Liver
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 22, 2026, 7:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

NCT03998514
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3, CB4211 Dose 4, CB4211 Dose 5, CB4211 Dose 6, CB4211 Dose TBD, Placebo
Drug
Lead sponsor
CohBar, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 22, 2026, 7:18 PM EDT